The company exhibits extreme negative operating leverage, with recent quarterly operating margins reaching -107.5% as fixed R&D and G&A costs continue to dwarf the nominal $25,000 in revenue reported for 2026Q1.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|
| Sales/Revenue | 345K | 320K | 0 | 0 | 0 | 0 | 0 | 120K | 1.46M | 1.46M | 143.28K | 362.29K | 9.97K | 0 |
| Revenue Growth % | - | - | - | - | - | - | -100% | -91.78% | 0.09% | 918.31% | -60.45% | 3532.23% | - | - |
| Cost of Goods Sold | -26K | 0 | 0 | 0 | 120K | 106K | 0 | 0 | 5.08M | 2.22M | 0 | 0 | 55.83K | 62.94K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | 347.87% | 152.19% | - | - | 559.7% | - |
| Gross Profit | 371K | 320K | 0 | 0 | -120K | -106K | 0 | 120K | -3.62M | -761.5K | 143.28K | 362.29K | -45.85K | -62.94K |
| Gross Margin % | 107.54% | 100% | - | - | - | - | - | 100% | -247.87% | -52.19% | 100% | 100% | -459.7% | - |
| Gross Profit Growth % | - | - | - | 100% | -13.21% | - | -100% | 103.32% | -375.35% | -631.48% | -60.45% | 890.13% | 27.15% | - |
| Operating Expenses | 12.63M | 12.93M | 27.24M | 17.13M | 34.46M | 26.56M | 8.32M | 17.73M | 1.36M | 3.08M | 4.63M | 1.76M | 22.81K | 18.24K |
| OpEx % of Revenue | - | 4039.06% | - | - | - | - | - | 14775.83% | 93.32% | 211.23% | 3232.12% | 485.48% | 228.67% | - |
| Selling, General & Admin | 6.11M | 6.32M | 11.44M | 10.03M | 9.96M | 12.36M | 4.1M | 3.87M | 1.28M | 3.07M | 272.39K | 89.15K | 0 | 0 |
| SG&A % of Revenue | - | 1976.25% | - | - | - | - | - | 3225% | 87.54% | 210.64% | 190.12% | 24.61% | - | - |
| Research & Development | 6.5M | 6.6M | 6.1M | 7.1M | 6.93M | 14.2M | 4.22M | 6.37M | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | 2062.81% | - | - | - | - | - | 5305.83% | - | - | - | - | - | - |
| Other Operating Expenses | 26K | 0 | 9.7M | 0 | 17.57M | 0 | 0 | 7.49M | 84.39K | 8.7K | 4.36M | 1.67M | 22.81K | 18.24K |
| Operating Income | -12.26M | -12.61M | -27.24M | -17.13M | -34.46M | -26.56M | -8.32M | -17.61M | -4.98M | -3.84M | -4.49M | -1.4M | -68.66K | -81.19K |
| Operating Margin % | -3552.75% | -3939.06% | - | - | - | - | - | -14675.83% | -341.19% | -263.43% | -3132.12% | -385.48% | -688.39% | - |
| Operating Income Growth % | - | 53.73% | -59.03% | 50.3% | -29.77% | -219.22% | 52.76% | -253.46% | -29.64% | 14.36% | -221.33% | -1933.98% | 15.43% | - |
| EBITDA | -12.31M | -12.62M | -27.23M | -17.09M | -34.4M | -26.45M | -8.23M | -17.56M | -4.95M | -3.83M | -4.21M | -1.13M | -45.85K | 0 |
| EBITDA Margin % | -3567.25% | -3943.13% | - | - | - | - | - | -14633.33% | -338.96% | -262.83% | -2937.94% | -312.28% | -459.72% | - |
| EBITDA Growth % | 52.7% | 53.66% | -59.33% | 50.32% | -30.07% | -221.27% | 53.12% | -254.75% | -29.08% | 8.9% | -272.07% | -2367.3% | -91706259.99% | - |
| D&A (Non-Cash Add-back) | -50K | -13K | 9K | 37K | 60K | 106K | 86K | 51K | 32.53K | 8.7K | 278.21K | 265.22K | 22.81K | 81.19K |
| EBIT | -11.06M | -11.05M | -24.24M | -11.32M | -17.36M | -25.88M | -6.1M | -15.66M | -4.93M | -3.84M | -4.49M | -1.4M | -68.66K | -81.19K |
| Net Interest Income | 385K | 616K | -120K | -476K | -193K | -640K | -320K | -3.31M | -233.24K | -2.42K | -43.7K | -39.4K | 0 | 0 |
| Interest Income | 742K | 801K | 533K | 22K | 30K | 0 | 0 | 7K | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 357K | 185K | 653K | 498K | 223K | 640K | 320K | 3.31M | 233.24K | 2.42K | 43.7K | 39.4K | 0 | 0 |
| Other Income/Expense | 1.01M | 1.37M | 2.35M | 5.31M | 16.88M | 41K | 1.9M | -1.37M | 1.53M | -1.15M | 37.99K | -130.58K | 0 | 0 |
| Pretax Income | -11.25M | -11.23M | -24.9M | -11.82M | -17.58M | -26.52M | -6.42M | -18.98M | -3.46M | -4.99M | -4.45M | -1.53M | -68.66K | -81.19K |
| Pretax Margin % | -3260.58% | -3509.69% | - | - | - | - | - | -15814.17% | -236.6% | -342.21% | -3105.61% | -421.53% | -688.39% | - |
| Income Tax | 0 | 0 | -381K | 83K | -1.52M | 133K | 198K | -4.58M | -1.07M | -95.09K | -766.89K | -380.16K | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 1.53% | -0.7% | 8.65% | -0.5% | -3.08% | 24.12% | 30.97% | 1.9% | 17.23% | 24.89% | 0% | 0% |
| Net Income | -11.25M | -11.23M | -24.52M | -11.9M | -16.06M | -26.65M | -6.6M | -14.31M | -2.29M | -4.9M | -3.68M | -1.15M | -68.66K | -81.19K |
| Net Margin % | -3260.58% | -3509.69% | - | - | - | - | - | -11927.5% | -156.97% | -335.69% | -2570.36% | -316.59% | -688.39% | - |
| Net Income Growth % | 51.94% | 54.19% | -105.99% | 25.89% | 39.74% | -303.64% | 53.87% | -524.39% | 53.2% | -32.99% | -221.08% | -1570.48% | 15.43% | - |
| Net Income (Continuing) | -11.25M | -11.23M | -24.52M | -11.9M | -16.06M | -26.65M | -6.62M | -14.4M | -2.39M | -4.9M | -3.68M | -1.15M | -68.66K | -81.19K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.82M | 4.1M | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.70 | -0.78 | -15.79 | -6031.31 | -31799.09 | -79074.18 | -999999.00 | -189613.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.06 | 0.00 |
| EPS Growth % | 94.18% | 95.06% | 99.74% | 81.03% | 59.79% | 95.34% | -795.85% | - | - | - | - | 100% | - | - |
| EPS (Basic) | - | -0.78 | -15.79 | -6031.31 | -31799.09 | -79074.18 | -999999.00 | -189613.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.06 | 0.00 |
| Diluted Shares Outstanding | 15.97M | 14.38M | 1.61M | 3.32M | 11.34K | 7.57K | 4 | 75.48K | 0 | 0 | 0 | 0 | 3K | 0 |
| Basic Shares Outstanding | 15.97M | 14.38M | 1.61M | 3.32M | 11.34K | 7.57K | 3.89K | 75.48K | 0 | 0 | 0 | 0 | 3K | 0 |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Binary clinical trial failure
As indicated by recent financial disclosures, Allarity’s revenue remains highly irregular, with a TTM figure of $320,000 that reflects non-operational licensing milestones rather than a sustainable commercial trajectory, leaving the company without a reliable foundation for long-term growth or predictable top-line expansion in the near term.
The absence of consistent revenue streams underscores the company's status as a pre-commercial entity reliant on transactional events. Investors should monitor whether future licensing agreements can provide a bridge to commercialization or if the current revenue profile will remain negligible relative to the firm's substantial operating expenses.
According to historical income statements, the company maintains a rigid cost structure dominated by R&D and G&A expenses, which consistently outpace revenue and necessitate ongoing capital infusions to sustain the clinical development of assets like Stenoparib, as evidenced by the persistent quarterly operating losses.
The concentration of spending in R&D suggests a management focus on clinical trial execution, yet the lack of operational efficiency remains a primary concern. Without a transition to a royalty-based model or successful product launch, the current cost structure appears to be a permanent drag on shareholder value.
Based on reported figures, Allarity exhibits extreme negative operating leverage, with operating margins reaching -3939.06% in recent periods, illustrating that the company's overhead and clinical trial costs are not scaling with its minimal, sporadic revenue, thereby intensifying the pressure on the firm's limited cash reserves.
The lack of scalability in the current operating model implies that the company is effectively a cash-burn vehicle rather than a traditional industrial entity. Any potential for positive operating leverage is entirely contingent upon the successful validation of the DRP platform and subsequent regulatory approval of its oncology assets.
As documented in SEC filings, the company's EPS figures are heavily distorted by frequent equity financing and stock-based compensation, which, when combined with recurring net losses, suggests that the quality of earnings is currently non-existent and secondary to the firm's ongoing survival-oriented capital allocation strategy.
The reliance on dilutive equity offerings to fund operations complicates the interpretation of per-share metrics, as the share count is subject to frequent adjustment. Investors should view the reported net losses as a reflection of the high-risk nature of the business model rather than a temporary accounting anomaly.
While the DRP platform offers a theoretical competitive advantage in patient selection, the company's precarious cash position of $14.7M, as reported in recent statements, suggests that the firm faces a significant risk of further dilution or insolvency if clinical trial milestones are not met promptly.
Short-term investors should be wary of the binary nature of the Stenoparib trials, which represent the primary catalyst for potential value creation or total loss. The market's skepticism, reflected in the current valuation, appears to be a rational response to the company's limited runway and the unproven commercial viability of its diagnostic-led approach.
Quick answers to the most common questions about buying ALLR stock.
For fiscal year 2025, Allarity Therapeutics, Inc. (ALLR) reported total revenue of $0.3M.
Allarity Therapeutics, Inc. (ALLR) reported a net loss of $11.2M for the fiscal year ending 2025.
Allarity Therapeutics, Inc. (ALLR) reported an operating income of $-12.6M, resulting in an operating profit margin of -3939.1%. This margin reflects the operational efficiency of the business before interest and taxes.
Allarity Therapeutics, Inc. (ALLR) generated $0.3M in gross profit for the year, representing a gross profit margin of 100.0%. This demonstrates the company's core pricing power and production efficiency.